A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase 4TerminatedNCT00312351

Eyetech Pharmaceuticals262 enrolled

Overview

The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

262

Conditions

Macular Degeneration

Interventions

Pegaptanib sodiumDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects of either gender, aged 50 years or greater. * Subfoveal choroidal neovascularization (CNV) due to AMD. * Best corrected visual acuity in the study eye between 20/40 and 20/320. * Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more. Exclusion Criteria: * Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.

Locations (1)

Charlotte Eye, Ear, Nose and Throat Associates, P.A.

Charlotte, North Carolina, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.